These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25836678)

  • 1. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
    Xie H; Chung JK; Mascelli MA; McCauley TG
    PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
    Chung JK; Brown E; Crooker B; Palmieri KJ; McCauley TG
    PLoS One; 2016; 11(10):e0164765. PubMed ID: 27764180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys.
    Felice BR; Wright TL; Boyd RB; Butt MT; Pfeifer RW; Pan J; Ruiz JA; Heartlein MW; Calias P
    Toxicol Pathol; 2011 Aug; 39(5):879-92. PubMed ID: 21628718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.
    Calias P; Papisov M; Pan J; Savioli N; Belov V; Huang Y; Lotterhand J; Alessandrini M; Liu N; Fischman AJ; Powell JL; Heartlein MW
    PLoS One; 2012; 7(1):e30341. PubMed ID: 22279584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
    Muenzer J; Hendriksz CJ; Fan Z; Vijayaraghavan S; Perry V; Santra S; Solanki GA; Mascelli MA; Pan L; Wang N; Sciarappa K; Barbier AJ
    Genet Med; 2016 Jan; 18(1):73-81. PubMed ID: 25834948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
    Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
    BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole Body and CNS Biodistribution of rhHNS in Cynomolgus Monkeys after Intrathecal Lumbar Administration: Treatment Implications for Patients with MPS IIIA.
    Chung JK; Pan L; Palmieri K; Youssef AS; McCauley TG
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29194406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
    Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
    Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
    Muenzer J; Vijayaraghavan S; Stein M; Kearney S; Wu Y; Alexanderian D
    Genet Med; 2022 Jul; 24(7):1437-1448. PubMed ID: 35588317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
    Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
    Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review.
    Al-Hertani W; Pathak RR; Evuarherhe O; Carter G; Schaeffer-Koziol CR; Whiteman DAH; Wright E
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
    Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan.
    Ueda K; Hokugo J
    Expert Opin Drug Saf; 2020 Jul; 19(7):891-901. PubMed ID: 32342708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.